Skip to main content
SpringerLink
Log in

Combining Lithium and Anticonvulsants in Bipolar Disorder: A Review

  • Published:
Annals of Clinical Psychiatry

Abstract

While the benefits of lithium in bipolar disorder are evident, its limitations as monotherapy are well recognized, particularly in bipolar depression. This has propelled trials of combined lithium–anticonvulsant therapy in many bipolar patients. The present review of the English-language literature examines both controlled and open studies of such combination therapy, including the risk of drug–drug interactions. Trials of lithium plus either carbamazepine or divalproex have generally produced favorable results, although increased rates of adverse effects may reduce treatment adherence. More recent reports suggest that lithium may be safely and effectively combined with lamotrigine, and perhaps with topiramate, although controlled studies are required. The combined use of lithium with newer, putative mood stabilizers, such as zonisamide or levetiracetam, cannot yet be recommended, but is an important area for future research. Provisional recommendations for combined treatment are provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA: Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002; 63:120–125

    Google Scholar 

  2. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L: Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am J Psychiatry 1995; 152:1130–1138

    Google Scholar 

  3. Bocchetta A, Chillotti C, Severino G, Ardau R, Del Zompo M: Carbamazepine augmentation in lithium-refractory bipolar patients: A prospective study on long-term prophylactic effectiveness. J Clin Psychopharmacol 1997; 17:92–96

    Google Scholar 

  4. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Jr, Chou JC, Keck PE, Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ: A randomized, placebocontrolled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57:481–489

    Google Scholar 

  5. Baldessarini RJ, Tondo L: Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000; 57:187–190

    Google Scholar 

  6. Schou M: Suicidal behavior and prophylactic lithium treatment of major mood disorders: A review of reviews. Suicide Life Threat Behav 2000; 30:289–293

    Google Scholar 

  7. Tondo L, Baldessarini RJ: Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000; 61 (Suppl 9):97–104

    Google Scholar 

  8. Strakowski SM, McElroy SL, Keck PE: Clinical efficacy of valproate in bipolar illness: Comparisons and contrasts with lithium. In: Halbreich U, Montgomery SA, eds. Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders.Washington, DC: American Psychiatric Press; 2000:143–157

    Google Scholar 

  9. Nemeroff CB: A never-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 2000; 61 (Suppl 13):19–25

    Google Scholar 

  10. Post RM, Denicoff KD, Frye MA, Leverich GS, Cora-Locatelli G, Kimbrell TA: Long-term outcome of anticonvulsants in affective disorders. In: Goldberg JF, Harrow M, eds. Bipolar Disorders. Washington, DC: American Psychiatric Press; 1999: 85–114

    Google Scholar 

  11. Kramlinger KG, Post RM: Adding lithium carbonate to carbamazepine: Antimanic efficacy in treatment-resistant mania. Acta Psychiatr Scand 1989; 79:378–385

    Google Scholar 

  12. Kramlinger KG, Post RM: The addition of lithium to carbamazepine: Antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry 1989; 46:794–800

    Google Scholar 

  13. Kramlinger KG, Post RM: Addition of lithium carbonate to carbamazepine: Hematological and thyroid effects. Am J Psychiatry 1990; 147:615–620

    Google Scholar 

  14. Physician's Desk Reference. Montvale, NJ: Medical Economics; 2002:432

  15. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP: The expert consensus guideline series: Medication treatment of bipolar disorders 2000. Postgraduate Medicine Special Report 2000(April):1–104

  16. SharmaV, Persad E, MazmanianD, Karunaratne K:Treatment of rapid-cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry 1993; 38:137–139

    Google Scholar 

  17. Schneider AL, Wilcox CS: Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients. J Affect Disord 1998; 47:201–205

    Google Scholar 

  18. McCoy L, Votolato NA, Schwarzkopf SB, Nasrallah HA: Clinical correlates of valproate augmentation in refractory bipolar disorder. Ann Clin Psychiatry 1993; 5:29–33

    Google Scholar 

  19. Calabrese JR, Shelton MD, Bowden CL, Rapport DJ, Suppes T, Shirley ER, Kimmel SE, Caban SJ: Bipolar rapid cycling: Focus on depression as its hallmark. J Clin Psychiatry 2001; 62 (Suppl 14):34–41

    Google Scholar 

  20. Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A, Keller MB: A pilot study of lithium carbonate plus divalproex for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997; 58:95-]99

    Google Scholar 

  21. Solomon DA, Keitner GI, Ryan CE, Miller IW: Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: A review. J Clin Psychopharmacol 1998; 18:38–49

    Google Scholar 

  22. Denicoff KD, Smith-Jackson EE, Bryan AL, Ali SO, Post RM: Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997; 154:1456–1458

    Google Scholar 

  23. Hachad H, Ragueneau-Majlessi, Levy RH: New antiepileptic drugs: Review on drug interactions. Ther Drug Monit 2002; 24:91–103

    Google Scholar 

  24. Calabrese JR, Shelton MD, Rapport DJ, Kimmel SE: Bipolar disorders and the effectiveness of novel anticonvulsants. J Clin Psychiatry 2002; 63 (Suppl 3):5–9.

    Google Scholar 

  25. Emrich HM: Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol 1990; 5:83–88

    Google Scholar 

  26. Calabrese JR, Rapport DJ, Shelton MD, Kujawa M, Kimmel SE: Clinical studies on the use of lamotrigine in bipolar disorder. Neuropsychobiology 1998; 38:185–191

    Google Scholar 

  27. Bowden CL, Calabrese JR, McElroy SL, Rhodes LJ, Keck PE, Jr, Cookson J, Anderson J, Bolden-Watson C, Ascher J, Monaghan E, Zhou J: The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999; 45:953–958

    Google Scholar 

  28. Fatemi SH, Rapport DJ, Calabrese JR, Thuras P: Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997; 58:522–527

    Google Scholar 

  29. Kotler M, Matar MA: Lamotrigine in the treatment of resistant bipolar disorder. Clin Neuropharmacol 1998; 21:65–67

    Google Scholar 

  30. Sporn J, Sachs G: The anticonvulsant lamotrigine in treatmentresistant manic-depressive illness. J Clin Psychopharmacol 1997; 17:185–189

    Google Scholar 

  31. Fogelson DL, Sternbach H: Lamotrigine treatment of rapid cycling bipolar disorder. J Clin Psychiatry 1997; 58:271–273

    Google Scholar 

  32. Zerjav-Lacombe S, Tabarsi E: Lamotrigine: A review of clinical studies in bipolar disorders. Can J Psychiatry 2001; 46:328–333

    Google Scholar 

  33. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD: Safety of long-term lamotrigine in epilepsy. Epilepsia 1997; 38:881–886

    Google Scholar 

  34. Messenheimer JA, Giorgi L, Risner ME: The tolerability of lamotrigine in children. Drug Saf 2000; 22:303–312

    Google Scholar 

  35. Chen C, Veronese L, Yin Y: The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol 2000; 50:193–195

    Google Scholar 

  36. Post RM, Frye MA, Denicoff KD, Speer AM, Weiss SRB, Leverich GS: Preliminary algorithms for treatment-resistant bipolar depression. In: Amsterdam JD, Hornig M, Nierenberg A, eds. Treatment-Resistant Mood Disorders. London: Cambridge University Press; 2001:350–404

    Google Scholar 

  37. McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, Brown ES, Nolen WA, Kupka RW, Rochussen J, Leverich GS, Post RM: Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47:1025–1033

    Google Scholar 

  38. Grunze HC, Normann C, Langosch J, Schaefer M, Amann B, Sterr A, Schloesser S, Kleindienst N, Walden J: Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry 2001; 62:464–468

    Google Scholar 

  39. Chengappa KNR, Gershon S, Levine J: The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disorders 2001; 3:215–232.

    Google Scholar 

  40. Doose DR, Kohl KA, Desai-Krieger D, Natarajan J, van Kammen PP: The efficacy of topiramate on lithium-serum concentration. Presented at the 37h Annual Meeting of the American College of Neuropsychopharmacology, Las Croabas, Puerto Rico, December 1998

  41. Chengappa KN, Rathore D, Levine J, Atzert R, Solai L, Parepally H, Levin H, Moffa N, Delaney J, Brar JS: Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disorders 1999; 1:42–53

    Google Scholar 

  42. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Ocatelli G, Leverich GS, Post RM: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607–614

    Google Scholar 

  43. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G: Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Bipolar Disorders 2000; 2:249–255

    Google Scholar 

  44. Jacobson SA, PiesRW, Greenblatt DJ: Handbook of Geriatric Psychopharmacology.Washington, DC: American Psychiatric Press; 2002

    Google Scholar 

  45. Ghaemi SN, Ko JY: Polypharmacy of bipolar disorder. In: Ghaemi SN, ed. Polypharmacy in Psychiatry. New York: Marcel Dekker; 2002:35–78

    Google Scholar 

  46. Greil W, Kruger R, Rosnagl G, et al.: Prophylactic treatment of affective disorders with carbamazepine and oxcarbazepine: An open, clinical trial. Presented at the 7thWorld Congress of Psychiatry, Vienna, Austria, July 1983

Download references

Author information

Authors and Affiliations

  1. Tufts University School of Medicine, Boston, Massachusetts

    Ronald Pies

  2. Harvard Medical School, Boston, Massachusetts

    Ronald Pies

Authors
  1. Ronald Pies
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pies, R. Combining Lithium and Anticonvulsants in Bipolar Disorder: A Review. Ann Clin Psychiatry 14, 223–232 (2002). https://doi.org/10.1023/A:1021969001231

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021969001231

Search

Navigation